

**Ipca Laboratories Limited**

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24239MH1949PLC007837

Tel: +91 22 6647 4444, E-mail : investors@ipca.com Website : www.ipca.com

**AUDITED STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2020**


Sr. No.	Particulars	Quarter Ended			Year Ended	
		March 31, 2020	Dec 31, 2019	March 31, 2019	March 31, 2020	March 31, 2019
		Audited*	Unaudited	Audited*	Audited	Audited
I	Revenue from operations	1004.79	1139.07	833.81	4367.43	3633.15
II	Other Income	13.30	17.83	14.58	64.69	54.59
III	<b>Total Income (I+II)</b>	<b>1018.09</b>	<b>1156.70</b>	<b>848.39</b>	<b>4432.12</b>	<b>3687.74</b>
IV	Expenses					
	a) Cost of materials consumed	371.06	350.63	266.14	1431.10	1098.02
	b) Purchases of stock-in-trade	50.85	53.98	44.04	204.65	167.87
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(94.97)	(23.08)	(41.21)	(155.05)	(106.14)
	d) Employee benefits expense	227.88	217.72	176.82	870.79	752.24
	e) Finance costs	3.47	3.80	6.25	15.79	18.49
	f) Depreciation and amortisation expense	45.38	46.16	41.61	178.69	171.88
	g) Other expenses	257.25	274.38	213.35	1101.18	1027.99
	<b>Total Expenses (IV)</b>	<b>860.92</b>	<b>923.59</b>	<b>707.00</b>	<b>3647.15</b>	<b>3130.35</b>
V	<b>Profit before exceptional items and tax (III-IV)</b>	<b>157.17</b>	<b>233.11</b>	<b>141.39</b>	<b>784.97</b>	<b>557.39</b>
VI	Exceptional items	-	-	-	-	-
VII	<b>Profit before tax (V-VI)</b>	<b>157.17</b>	<b>233.11</b>	<b>141.39</b>	<b>784.97</b>	<b>557.39</b>
VIII	Tax Expense					
	-Current tax	28.18	40.78	30.90	137.98	119.90
	-Short / (Excess) provision of earlier years	-	-	-	-	(5.02)
	-Deferred tax liability / (asset) including MAT credit	1.23	(4.30)	1.02	(5.47)	(12.40)
IX	<b>Profit for the period from continuing operations (VI-VIII)</b>	<b>127.76</b>	<b>196.63</b>	<b>109.47</b>	<b>652.46</b>	<b>454.91</b>
X	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss -					
	- Actuarial gain/(loss)	(2.64)	(0.61)	(4.66)	(7.21)	(1.39)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.45	0.11	1.00	1.25	0.30
	B (i) Items that will be reclassified to profit or loss					
	- Exchange difference in translating the financial statement of foreign operation	(0.62)	0.23	(0.26)	(0.60)	(0.64)
	- Gain/(loss) on cash flow hedge	(0.76)	0.12	(0.36)	(1.47)	(3.41)
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.24	(0.04)	-	0.36	-
	<b>Other Comprehensive income / (Loss) for the period net of tax (X)</b>	<b>(3.33)</b>	<b>(0.19)</b>	<b>(4.28)</b>	<b>(7.67)</b>	<b>(5.14)</b>
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>124.43</b>	<b>196.44</b>	<b>105.19</b>	<b>644.79</b>	<b>449.77</b>
XII	Paid-up equity share capital (Face value of ₹ 2/- each)	25.27	25.27	25.27	25.27	25.27
XIII	Other Equity	-	-	-	3,640.33	3111.39
XIV	Share Warrant	-	-	-	11.94	-
XV	<b>Net Worth</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3,677.54</b>	<b>3136.66</b>
XVI	Earnings per share (of ₹ 2/- each) (Not annualised):					
	Basic (₹)	10.11	15.56	8.67	51.64	36.01
	Diluted (₹)	10.10	15.56	8.67	51.60	36.01



## AUDITED STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT MARCH 31, 2020

(₹ Crores)


Sr. No.	Particulars	Unaudited	Audited
		March 31, 2020	March 31, 2019
<b>A</b>	<b>ASSETS :</b>		
<b>1</b>	<b>Non-current assets :</b>		
(a)	Property, Plant and Equipment	1772.78	1706.35
(b)	Capital work-in-progress	69.77	35.72
(c)	Goodwill	23.61	23.61
(d)	Other Intangible assets	18.45	10.14
(e)	Intangible assets under development	14.42	30.24
(f)	Right of use asset	26.13	-
(g)	Financial Assets		
	(i) Investments in Subsidiary/Joint Venture/Associate	410.47	231.86
	(ii) Other investments	-	-
	(iii) Loans	98.98	116.96
	(iv) Others	10.64	3.24
(h)	Other non-current assets	27.21	13.87
	<b>Total Non current assets</b>	<b>2472.46</b>	<b>2171.99</b>
<b>2</b>	<b>Current assets :</b>		
(a)	Inventories	1266.96	1055.55
(b)	Financial Assets		
	(i) Investments	238.25	90.38
	(ii) Trade receivables	839.13	632.06
	(iii) Cash and cash equivalents	35.14	258.69
	(iv) Bank Balance other than (iii) above	117.26	1.12
	(v) Loans	3.22	2.12
	(vi) Others	80.45	104.51
(c)	Current tax assets	-	-
(d)	Other current assets	131.70	141.12
	<b>Total Current assets</b>	<b>2712.11</b>	<b>2285.55</b>
	<b>Total Assets</b>	<b>5184.57</b>	<b>4457.54</b>
<b>B</b>	<b>EQUITY AND LIABILITIES :</b>		
	<b>Equity :</b>		
(a)	Equity Share Capital	25.27	25.27
(b)	Share Warrant	11.94	-
(c)	Other Equity	3640.33	3111.39
	<b>Total Equity</b>	<b>3677.54</b>	<b>3136.66</b>
	<b>Liabilities :</b>		
<b>1</b>	<b>Non-current liabilities :</b>		
(a)	Financial Liabilities		
	(i) Borrowings	78.38	133.94
	(ii) Lease liability	13.02	-
	(iii) Other financial liabilities	-	-
(b)	Provisions	30.98	25.28
(c)	Deferred tax liabilities (net)	140.79	146.26
(d)	Other non-current liabilities	2.26	1.56
	<b>Total Non current liabilities</b>	<b>265.43</b>	<b>307.04</b>
<b>2</b>	<b>Current liabilities :</b>		
(a)	Financial Liabilities		
	(i) Borrowings	309.27	195.86
	(ii) Lease liability	5.87	-
	(iii) Trade payables		
	- Dues of micro and small enterprises	8.28	4.34
	- Dues of others	529.57	459.75
	(iv) Other financial liabilities	137.74	196.91
(b)	Current Tax Liabilities (net)	6.75	16.55
(c)	Provisions	92.85	70.40
(d)	Other current liabilities	151.27	70.03
	<b>Total Current liabilities</b>	<b>1241.60</b>	<b>1043.84</b>
	<b>Total Equity and Liabilities</b>	<b>5184.57</b>	<b>4457.54</b>



**Notes:**


- 1 The above audited standalone financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors at their meeting held on June 16, 2020.
- 2 The Company's Resolution Plan under the Insolvency and Bankruptcy Code, 2016 for Noble Explochem Ltd. (NEL) was approved by the National Company Law Tribunal (NCLT) vide its order dated January 22, 2020. Pursuant thereto, the Company has discharged its total obligation and has acquired control over NEL's vast land bank and infrastructure facility near Nagpur. As per the Resolution Plan, on approval by the NCLT, NEL merged with the Company with effect from the Completion Date without obtaining any separate order from NCLT. As per the aforesaid plan NEL's entire capital gets cancelled. The Company has recognised immovable properties, plant and machineries and other assets acquired at its respective fair value in terms of Ind AS 16 on Property, Plant and Equipment based on valuation reports of authorized valuers appointed by the Resolution Professionals. The Company proposes to use these assets to set up manufacturing unit(s) for manufacturing of Drug Intermediates and Active Pharmaceutical Ingredients.
- 3 Being manufacturers of pharmaceuticals, the operations of the Company were exempted from lockdown declared by both the Central and State Governments in the wake of Covid - 19 pandemic. The Company continued with the manufacturing operations at all its manufacturing sites albeit with challenges such as shortage of manpower, availability of materials and disruptions in the logistics and supply chain. The Company has considered the possible effects that may result due to the lockdown announced consequent to outbreak of Covid -19 on the carrying amounts of property, plant and equipment, investments, inventories, receivables and other current assets. Based on internal and external sources of information and economic forecasts, the Company expects the carrying amount of these assets will be recovered and will continue to have sufficient liquidity to fund its business operations as well as expansion plans. However, a definitive assessment of the impact, at this stage, is not possible in view of the highly uncertain economic environment and the situation is still evolving.
- 4 \*The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figures in respect of the full financial year ended March 31, and unaudited year-to-date figures up to the third quarter ended December 31, which were subjected to limited review.
- 5 The Company has only one reportable primary business segment viz. 'Pharmaceuticals'.
- 6 Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period.

Place : Mumbai,  
Date : June 16, 2020

SIGNED FOR IDENTIFICATION  
BY  
  
G. M. KAPADIA & CO.  
MUMBAI.


By Order of the Board  
For Ipca Laboratories Limited


  
Premchand Godha  
Chairman & Managing Director  
(DIN 00012691)




**Audited Statement of Standalone Cash Flow for the Year ended March 31, 2020**

	2019-20 (₹ Crores)	2018-19 (₹ Crores)
<b>A. Cash Flow from Operating Activities</b>		
1) Net profit before taxation and extraordinary item		
Adjustments for :	784.97	557.39
Depreciation, amortisation and impairment expense	178.69	171.88
(Profit) / Loss on sale of Property, plant & equipment	(7.86)	0.72
Net gain on financial asset through FVTPL	(0.68)	(0.16)
Adjustment on account of Revenue from contract with customers	-	2.04
Property, plant & equipment scrapped/ transferred	1.42	0.86
Miscellaneous Income	-	(1.00)
Sundry balances written off/(back)	(2.00)	(2.34)
Provision for doubtful debts / advances	4.59	0.12
Provision for diminution in value of Investments	1.15	-
Bad debts written off	(0.13)	2.02
Unwinding of Lease Rent	(6.08)	4.38
Employee Stock Option forfeited	-	0.01
Unrealised foreign exchange (gain) / loss	21.76	5.08
Interest Income	(31.96)	(27.31)
Interest expense	15.79	18.49
<b>2) Operating profit before working capital changes</b>	<b>174.69</b>	<b>174.79</b>
Decrease / (Increase) in inventories	(211.41)	(182.38)
Decrease / (increase) in Trade Receivables	(211.20)	(35.52)
Decrease / (increase) in Other Financial assets	3.17	(6.18)
Decrease / (increase) in Other assets	4.74	2.15
Increase / (Decrease) in Trade Payables	71.31	50.35
Increase / (Decrease) in Other Financial liabilities	(19.64)	1.54
Increase / (Decrease) in Other liabilities	81.94	39.67
Increase / (Decrease) in Provisions	22.19	1.50
<b>3) Cash generated from operation</b>	<b>(258.90)</b>	<b>(128.87)</b>
Income tax paid (net)	700.76	603.31
Net cash from operating activities	(146.41)	(107.66)
<b>B. Cash Flow from Investing Activities</b>	<b>554.35</b>	<b>495.65</b>
Purchase of Property, plant & equipment including capital Work in progress and intangible assets	(273.07)	(67.41)
Investment in subsidiaries	(26.74)	(83.40)
Consideration towards Business combination	(108.71)	-
Redemption of investment in subsidiaries	5.12	12.56
Investment in Associates	(49.43)	(14.41)
Investment in Joint Venture	-	(0.33)
Loan given to Associate	14.85	-
Loan given to Joint Venture	1.20	(1.36)
Proceeds from Sale of Property, Plant and Equipment	12.70	1.78
Capital Investment subsidy received	-	14.86
Movement in other bank balances	(116.41)	0.17
Interest received	42.36	14.56
Net cash from / (used) in Investing activities	(498.13)	(122.98)
<b>C. Cash Flow from Financing Activities</b>		
Issue of Share Capital	-	4.57
Issue of Share warrant	11.94	-
Increase / (decrease) in short term borrowings	106.69	(40.43)
Repayment of long-term borrowings	(115.22)	(154.91)
Interest paid	(14.32)	(16.66)
Dividend & dividend tax paid	(121.68)	(15.40)
Net cash from (used in) financing activities	(132.59)	(222.83)
<b>Net Increase / (decrease) in cash and cash equivalents (A + B + C)</b>	<b>(76.37)</b>	<b>149.84</b>
Cash and cash equivalents at beginning of year	348.44	198.60
Cash and cash equivalents at end of year	272.07	348.44
Components of cash & cash equivalents :		
Cash and cheques on hand	0.43	0.76
Balance with banks	34.71	257.93
Mutual Funds	238.25	90.38
Less : Fair value (gain) / loss on Mutual funds	(1.32)	(0.63)
	236.93	89.75
	272.07	348.44

SIGNED FOR IDENTIFICATION  
 BY   
**G. M. KAPADIA & CO.**  
**MUMBAI.**

By Order of the Board  
 For Ipca Laboratories Limited  
  
 Premchand Godha  
 Chairman & Managing Director  
 (DIN 00012691)

Place : Mumbai,  
 Date : June 16, 2020



**Ipca Laboratories Limited**

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067


CIN : L24239MH1949PLC007837

Tel: +91 22 6647 4444, E-mail : investors@ipca.com Website : www.ipca.com

**AUDITED STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2020**

(₹ Crores)

Sr. No.	Particulars	Quarter Ended			Year Ended	
		March 31, 2020	December 31, 2019	March 31, 2019	March 31, 2020	March 31, 2019
		Audited*	Unaudited	Unaudited	(Audited)	(Audited)
I	Revenue from operations	1073.76	1212.86	879.61	4648.71	3773.18
II	Other Income	13.73	18.13	15.26	67.00	57.68
III	<b>Total Income (I+II)</b>	<b>1087.49</b>	<b>1230.99</b>	<b>894.87</b>	<b>4715.71</b>	<b>3830.86</b>
IV	Expenses					
	a) Cost of materials consumed	377.68	359.92	268.45	1460.37	1106.08
	b) Purchase of stock-in-trade	85.51	96.68	92.22	359.88	249.07
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(98.60)	(32.79)	(53.98)	(176.12)	(115.42)
	d) Employee benefits expense	242.18	231.30	187.10	921.23	787.40
	e) Finance costs	3.67	4.01	6.44	16.50	18.87
	f) Depreciation and amortisation expense	63.94	50.83	44.76	210.50	182.42
	g) Other expenses	298.53	284.09	221.24	1176.65	1054.17
	<b>Total Expenses (IV)</b>	<b>972.91</b>	<b>994.04</b>	<b>766.23</b>	<b>3969.01</b>	<b>3282.59</b>
V	<b>Profit from ordinary activity before share of profit of associate &amp; joint venture, exceptional item &amp; tax (III - IV)</b>	<b>114.58</b>	<b>236.95</b>	<b>128.64</b>	<b>746.70</b>	<b>548.27</b>
VI	Share of Profit / (loss) of associates & joint venture accounted by using the equity method	(2.33)	(2.52)	(0.97)	(7.81)	(1.81)
VII	<b>Profit before exceptional items and tax (V+VI)</b>	<b>112.25</b>	<b>234.43</b>	<b>127.67</b>	<b>738.89</b>	<b>546.46</b>
VIII	Exceptional items	-	-	-	-	-
IX	<b>Profit before tax (VII - VIII)</b>	<b>112.25</b>	<b>234.43</b>	<b>127.67</b>	<b>738.89</b>	<b>546.46</b>
X	Tax Expense					
	Current tax	28.91	40.95	30.98	140.59	121.81
	Short / (Excess) provision of earlier years	0.33	-	(0.42)	0.52	(5.44)
	Deferred tax liability / (asset) including MAT credit	(0.04)	(4.06)	1.09	(5.78)	(12.13)
XI	<b>Profit for the period from continuing operations (IX-X)</b>	<b>83.05</b>	<b>197.54</b>	<b>96.02</b>	<b>603.56</b>	<b>442.22</b>
XII	Other Comprehensive Income					
	A. (i) Items that will not be reclassified to profit or loss					
	-Actuarial gain/(loss)	(2.83)	(0.61)	(4.66)	(7.40)	(1.39)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.50	0.11	1.00	1.30	0.30
	B. (i) Items that will be reclassified to profit or loss					
	-Exchange difference in translating the financial statement of foreign operation	3.93	4.06	(0.93)	11.10	1.07
	-Gain/(loss) on cash flow hedge	(0.76)	0.12	(0.36)	(1.47)	(3.41)
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.24	(0.04)	-	0.36	-
	C. Share of OCI from investment in associates	0.01	(0.13)	(0.16)	(0.36)	(0.40)
	<b>Other Comprehensive Income / (Loss) for the period, net of tax</b>	<b>1.09</b>	<b>3.51</b>	<b>(5.11)</b>	<b>3.53</b>	<b>(3.83)</b>
XIII	<b>Total Comprehensive Income for the period (XI + XII)</b>	<b>84.14</b>	<b>201.05</b>	<b>90.91</b>	<b>607.09</b>	<b>438.39</b>
	<b>Profit for the year attributable to :</b>					
	Owners of the parent	86.01	197.61	98.55	606.32	444.83
	Non-controlling interest - profit / (loss)	(2.96)	(0.07)	(2.53)	(2.76)	(2.61)
		<b>83.05</b>	<b>197.54</b>	<b>96.02</b>	<b>603.56</b>	<b>442.22</b>
	<b>Other Comprehensive Income for the year attributable to :</b>					
	Owners of the parent	0.64	3.43	(3.72)	2.68	(3.08)
	Non-controlling interest - profit / (loss)	0.45	0.08	(1.39)	0.85	(0.75)
		<b>1.09</b>	<b>3.51</b>	<b>(5.11)</b>	<b>3.53</b>	<b>(3.83)</b>
	<b>Total Comprehensive Income for the year attributable to :</b>					
	Owners of the parent	86.65	201.04	94.83	609.00	441.75
	Non-controlling interest - profit / (loss)	(2.51)	0.01	(3.92)	(1.91)	(3.36)
		<b>84.14</b>	<b>201.05</b>	<b>90.91</b>	<b>607.09</b>	<b>438.39</b>
XIV	Paid-up equity share capital (Face value of ₹ 2/- each)	25.27	25.27	25.27	25.27	25.27
XV	Other Equity	-	-	-	3590.27	3097.12
XVI	Share Warrant	-	-	-	11.94	-
XVII	Net Worth	-	-	-	3627.48	3122.39
XVIII	Earning per equity share ( of ₹ 2/- each) (Not annualised):					
	Basic ( ₹ )	6.57	15.63	7.60	47.77	35.01
	Diluted ( ₹ )	6.57	15.63	7.60	47.73	35.01



## AUDITED STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT MARCH 31, 2020

(₹ Crores)

Sr. No.	Particulars	March 31, 2020 (Audited)	March 31, 2019 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non Current Assets :</b>		
(a)	Property, plant and equipment	1896.32	1746.47
(b)	Capital work-in-progress	70.80	36.09
(c)	Goodwill on consolidation	38.83	23.59
(d)	Goodwill on acquisition	23.61	23.61
(e)	Other Intangible assets	121.90	146.71
(f)	Intangible assets under development	14.42	30.24
(g)	Right of use asset	26.13	-
(h)	Investment accounted for using the equity method	33.66	30.05
(i)	Financial Assets		
	(i) Investments	37.65	-
	(ii) Loans	99.41	117.01
	(iii) Others	11.22	3.24
(j)	Deferred tax assets (net)	2.01	1.84
(k)	Other non-current assets	28.16	14.07
	<b>Total Non current assets</b>	<b>2404.12</b>	<b>2,172.92</b>
<b>2</b>	<b>Current Assets :</b>		
(a)	Inventories	1323.12	1072.50
(b)	Financial Assets		
	(i) Investments	238.25	90.38
	(ii) Trade receivables	895.20	681.51
	(iii) Cash and cash equivalents	58.46	281.18
	(iv) Bank balance other than (iii) above	122.46	1.12
	(v) Loans	2.95	2.57
	(vi) Others	81.04	105.13
(c)	Current tax assets (net)	-	-
(d)	Other current assets	134.23	143.36
	<b>Total Current assets</b>	<b>2855.71</b>	<b>2377.75</b>
	<b>Total Assets</b>	<b>5259.83</b>	<b>4550.67</b>
	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity :</b>		
(a)	Equity Share Capital	25.27	25.27
(b)	Share Warrants	11.94	-
(c)	Other Equity	3590.27	3097.12
	Equity attributable to shareholders of the Holding Company	3627.48	3122.39
	Non controlling interest	13.63	15.54
	<b>Total Equity</b>	<b>3641.11</b>	<b>3137.93</b>
<b>2</b>	<b>Liabilities :</b>		
<b>I</b>	<b>Non Current Liabilities :</b>		
(a)	Financial Liabilities		
	(i) Borrowings	102.97	140.85
	(ii) Lease Liability	13.02	-
	(iii) Other financial liabilities	-	-
(b)	Provisions	32.23	25.28
(c)	Deferred tax liabilities (net)	141.82	147.55
(d)	Other non-current liabilities	2.26	1.56
	<b>Total Non current liabilities</b>	<b>292.30</b>	<b>315.24</b>
<b>II</b>	<b>Current Liabilities :</b>		
(a)	Financial Liabilities		
	(i) Borrowings	310.95	209.69
	(ii) Lease Liability	5.87	-
	(iii) Trade payables		
	Dues of Micro and small enterprises	8.28	4.34
	Dues of others	601.57	519.98
	(iv) Other financial liabilities	139.37	197.59
(b)	Current tax liabilities (net)	7.35	18.35
(c)	Provisions	93.70	70.40
(d)	Other current liabilities	159.33	77.15
	<b>Total Current liabilities</b>	<b>1326.42</b>	<b>1097.50</b>
	<b>Total Equity and Liabilities</b>	<b>5259.83</b>	<b>4550.67</b>



## Notes:

- 1 The above audited consolidated financial statements relates to Ipca Laboratories Ltd. and its Subsidiary Companies, Associates and Joint Venture. The consolidated financial statements have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015
- 2 The above audited consolidated financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on June 16, 2020.
- 3 The Holding Company's Resolution Plan under the Insolvency and Bankruptcy Code, 2016 for Noble Explochem Ltd. (NEL) was approved by the National Company Law Tribunal (NCLT) vide its order dated January 22, 2020. Pursuant thereto, the Holding Company has discharged its total obligation and has acquired control over NEL's vast land bank and infrastructure facility near Nagpur. As per the Resolution Plan, on approval by the NCLT, NEL merged with the Holding Company with effect from the Completion Date without obtaining any separate order from NCLT. As per the aforesaid plan NEL's entire capital gets cancelled. The Holding Company has recognised immovable properties, plant and machineries and other assets acquired at its respective fair value in terms of Ind AS 16 on Property, Plant and Equipment based on valuation reports of authorized valuers appointed by the Resolution Professionals. The Holding Company proposes to use these assets to set up manufacturing unit(s) for manufacturing of Drug Intermediates and Active Pharmaceutical Ingredients.
- 4 Being manufacturers of pharmaceuticals, the operations of the Company in India were exempted from lockdown declared by both the Central and State Governments in the wake of Covid - 19 pandemic. The Group continued with the manufacturing operations at all its manufacturing sites albeit with challenges such as shortage of manpower, availability of materials and disruptions in the logistics and supply chain. The Group has considered the possible effects that may result due to the lockdown announced consequent to outbreak of Covid -19 on the carrying amounts of property, plant and equipment, investments, inventories, receivables and other current assets. Based on internal and external sources of information and economic forecasts, the Group expects the carrying amount of these assets will be recovered and will continue to have sufficient liquidity to fund its business operations as well as expansion plans. However, a definitive assessment of the impact, at this stage, is not possible in view of the highly uncertain economic environment and the situation is still evolving.
- 5 In accordance with Ind AS-108 "Operating Segments", the Group has only one reportable primary business segment i.e. Pharmaceuticals. However, the Group has secondary geographical segment which is disclosed in Consolidated Financial Statements as per Ind AS-108.

Information about secondary geographical segments as per Consolidated Financial Statements:

Particulars	₹ Crores	
	2019-20	2018-19
Segment Revenue		
- India	2470.48	1860.20
- Outside India	2178.23	1912.98
Total	4648.71	3773.18

The segment asset and segment capital expenditure attributable to the segment "outside India" is less than 10% of the respective total asset and total capital expenditure and therefore not disclosed separately.

- 6 \*The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figures in respect of the full financial year ended March 31, and unaudited year-to-date figures up to the third quarter ended December 31, which were subjected to limited review.
- 7 Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period.

Place : Mumbai,  
Date : June 16, 2020

SIGNED FOR IDENTIFICATION  
BY  
*G. M. Kapadia*  
G. M. KAPADIA & CO.  
MUMBAI.

By Order of the Board  
For Ipca Laboratories Limited


*Premchand Godha*  
Premchand Godha  
Chairman & Managing Director  
(DIN 00012691)




**Audited Statement of Consolidated Cash Flow for the Year ended March 31, 2020**

	2019-20 (₹ Crores)	2018-19 (₹ Crores)
<b>A. Cash Flow from Operating Activities</b>		
1) Net profit before taxation and extraordinary item		546.46
Adjustments for :	738.89	
Depreciation and Amortisation	210.50	182.42
Impairment of Intangibles	27.64	
(Profit) / Loss on sale of Property, plant & equipment	(7.81)	0.63
Share of profit / (loss) of Associates & Joint venture accounted by using the equity method	7.81	1.81
Net gain on financial asset through FVTPL	(0.68)	(0.16)
Adjustment on account of Revenue from contract with customers	-	2.04
Interest income on financial assets at amortised cost	(5.36)	(5.06)
Property, plant & equipment scrapped/ transferred	1.42	0.92
Miscellaneous Income	-	(1.00)
Sundry balances written off/(back)	(2.60)	(2.34)
Provision for doubtful debts / advances	4.56	0.12
Bad debts written off	0.44	2.02
Unwinding of Lease Rent	(6.08)	4.38
Employee Stock Option forfeited	-	0.01
Unrealised foreign exchange (gain) / loss	21.89	5.08
Interest income	(26.94)	(22.38)
Interest expense	16.50	18.87
	241.29	187.36
2) Operating profit before working capital changes	980.18	733.82
Decrease / (Increase) in inventories	(239.86)	(191.91)
Decrease / (increase) in Trade Receivables	(187.41)	(75.49)
Decrease / (Increase) in Other Financial assets	4.13	(4.41)
Decrease / (increase) in Other assets	7.50	2.47
Increase / (Decrease) in Trade Payables	68.28	101.88
Increase / (Decrease) in Other Financial liabilities	(20.81)	(0.29)
Increase / (Decrease) in Other liabilities	82.71	44.28
Increase / (Decrease) in Provisions	21.77	1.50
	(263.69)	(121.97)
3) Cash generated from operation	716.49	611.85
Income tax paid (net)	(152.22)	(110.82)
Net cash from operating activities	564.27	501.03
<b>B. Cash Flow from Investing Activities</b>		
Purchase of Property, plant & equipment, Intangibles including Capital Work in progress	(306.28)	(180.54)
Consideration towards Business combination	(108.72)	
Investment including Equity Shares, Share Warrants and Preference Shares in Associates	(49.43)	(14.41)
Investment in Joint Venture	-	(0.33)
Loan given to Associate	14.85	
Loan given to Joint Venture	1.20	(1.36)
Proceeds from Sale of Property, Plant and Equipment	12.65	1.87
Capital Investment subsidy received	-	14.86
Movement in other bank balances	(116.62)	0.16
Interest received	42.70	14.69
Net cash from / (used) in Investing activities	(509.65)	(165.06)
<b>C. Cash Flow from Financing Activities</b>		
Issue of Share Capital	-	4.57
Issue of Share Warrant	11.94	
Increase / (decrease) in short term borrowings	91.30	(26.60)
Proceeds from long-term borrowings	24.58	6.91
Repayment of long-term borrowings	(122.19)	(154.91)
Increase in Minority Interest	-	18.90
Interest paid	(14.43)	(16.66)
Dividend & dividend tax paid	(121.66)	(15.41)
Net cash from (used in) financing activities	(130.46)	(183.20)
Net Increase / (decrease) in cash and cash equivalents (A + B + C)	(75.84)	152.77
Cash and cash equivalents at beginning of year	370.92	218.15
Movement due to Business Acquisition	0.31	
Cash and cash equivalents at end of year	295.39	370.92
Components of cash & cash equivalents :		
Cash and cheques on hand	0.48	1.14
Balance with banks	57.98	280.04
Mutual Funds	238.25	90.38
Less : Fair value (gain) / loss on Mutual funds	(1.32)	(0.64)
	236.93	89.74
	295.39	370.92

Place : Mumbai,  
Date : June 16, 2020

SIGNED FOR IDENTIFICATION  
BY   
**G. M. KAPADIA & CO.**  
MUMBAI.

By Order of the Board  
For Ipca Laboratories Limited

  
Premchand Godha  
Chairman & Managing Director  
(DIN 00012691)





## PRESS RELEASE

### Ipca Laboratories Q4 FY20 Financial Results

**Mumbai, June 16, 2020** : Ipca Laboratories Limited today announced its audited financial results for the fourth quarter and financial year ended 31<sup>st</sup> March, 2020.

#### Key Financials of Q4 FY20

- Standalone Net total Income up 20% at Rs. 1018.09 crores.
- Consolidated Net total Income up 22% at Rs. 1087.49 crores.
- Indian formulations income up 21% at Rs. 430.96 crores.
- Exports Income up 18% at Rs. 492.66 crores.
- Standalone EBITDA margin (before forex (gain)/loss) @ 22.29% in Q4 FY20 as against @ 21.20% in Q4 FY19.
- Consolidated EBITDA margin @ 21.47% in Q4 FY20 as against @ 20.09% in Q4 FY19.
- Standalone Net Profit at Rs. 127.76 crores up 17%.
- Consolidated Net Profit at Rs. 83.05 crores decreased by 14% after impairment of Intangible Assets of Rs. 27.64 crores of a US subsidiary.

Standalone Q4 FY20 at a glance			(Rs. Crores)
Particulars	Q4 FY20	Q4 FY19	Growth
Net Total Income	1018.09	848.39	20%
Export Income	492.66	419.16	18%
EBITDA before Forex (gain) / loss	226.90	179.90	26%
Forex (gain) / loss	20.88	(9.35)	-
Finance Cost	3.47	6.25	-44%
Depreciation and Amortisation	45.38	41.61	9%
Tax Expense	29.41	31.92	-8%
Net Profit after tax	127.76	109.47	17%
Earnings per share of Rs. 2/- each (Rs.)	10.11	8.67	17%

Consolidated Q4 FY20 at a glance			(Rs. Crores)
Particulars	Q4 FY20	Q4 FY19	Growth
Consolidated Net-Total Income	1087.49	894.87	22%
Consolidated EBITDA before Forex (gain) / loss and impairment:	233.45	179.80	30%
Share of (profit) / loss of associates & joint venture	2.33	0.97	140%
Forex (gain) / loss	23.62	(0.04)	-
Finance Cost	3.67	6.44	-43%
Depreciation and Amortisation	63.94	44.76	43%
Impairment of Intangible Assets	27.64	-	-
Tax Expense	29.20	31.65	-8%
Consolidated Net Profit after tax	83.05	96.02	-14%
Consolidated Earnings per share of Rs. 2/- each (Rs.)	6.57	7.60	-14%


Ipca Laboratories Ltd.

www.ipca.com

Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India. | T: +91-22 6210 5000 F: +91-22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837



Q4 FY20 Revenue break-up			
(Rs. Crores)			
Particulars	Q4 FY20	Q4 FY19	Growth
<b>Formulations</b>			
Domestic	430.96	355.70	21%
<b>Exports</b>			
Branded	76.72	94.59	-19%
Institutional	39.71	40.82	-3%
Generics	166.04	118.19	40%
<b>Total Formulations</b>	<b>713.43</b>	<b>609.30</b>	<b>17%</b>
<b>APIs</b>			
Domestic	64.88	46.04	41%
Exports	210.19	165.56	27%
<b>Total APIs</b>	<b>275.07</b>	<b>211.60</b>	<b>30%</b>
Other Operating Income	16.29	12.91	26%
Standalone Revenue from Operations	1004.79	833.81	21%
Revenue from Operations - Subsidiaries	68.97	45.80	51%
Consolidated Revenue from Operations	1073.76	879.61	22%
Other Income	13.73	15.26	-10%
<b>Consolidated Net Total Income</b>	<b>1087.49</b>	<b>894.87</b>	<b>22%</b>

#### Key Financials of FY20

- Standalone Net Total Income up 20% at Rs. 4432.12 crores.
- Consolidated Net Total Income up 23% at Rs. 4715.71 crores.
- Indian formulations income up 16% at Rs. 1912.61 crores.
- Exports Income up 24% at Rs. 2143.75 crores.
- Standalone EBITDA margin (before forex (gain) / loss) @ 22.41% in FY20 as against @ 20.75% in FY19
- Consolidated EBITDA margin @ 21.55% in FY20 as against @ 20.05% in FY19
- Standalone Net Profit at Rs. 652.46 crores up 43%.
- Consolidated Net Profit at Rs. 603.56 crores up 36%


Standalone FY20 at a glance			
(Rs. Crores)			
Particulars	FY20	FY19	Growth
Net Total Income	4432.12	3687.74	20%
Export Income	2143.75	1730.84	24%
EBITDA before Forex (gain) / loss	993.41	765.26	30%
Forex (gain) / loss	13.96	17.50	-20%
Finance Cost	15.79	18.49	-15%
Depreciation and Amortisation	178.69	171.88	4%
Tax Expense	132.51	102.48	29%
Net Profit after tax	652.46	454.91	43%
Earnings per share of Rs. 2/- each (Rs.)	51.64	36.01	43%

ipca Laboratories Ltd.  
www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837




Consolidated FY20 at a glance		(Rs. Crores)	
Particulars	FY20	FY19	Growth
Consolidated Net Total Income	4715.71	3830.86	23%
Consolidated EBITDA before Forex (gain) / loss and impairment	1016.40	768.20	32%
Share of (profit) / loss of associates & joint venture	7.81	1.81	-
Forex (gain) / loss	15.06	18.64	-19%
Finance Cost	16.50	18.87	-13%
Depreciation and Amortisation	210.50	182.42	15%
Impairment of Intangible Assets	27.64	-	-
Tax Expense	135.33	104.24	30%
Consolidated Net Profit after tax	603.56	442.22	36%
Consolidated Earnings per share of Rs. 2/- each (Rs.)	47.77	35.01	36%

FY20 Revenue break-up		(Rs. Crores)	
Particulars	FY20	FY19	Growth
<b>Formulations</b>			
Domestic	1912.61	1646.83	16%
<b>Exports</b>			
Branded	381.53	360.94	6%
Institutional	176.31	164.95	7%
Generics	663.71	522.37	27%
<b>Total Formulations</b>	<b>3134.16</b>	<b>2695.09</b>	<b>16%</b>
<b>APIs</b>			
Domestic	250.93	201.98	24%
Exports	922.20	682.58	35%
<b>Total APIs</b>	<b>1173.13</b>	<b>884.56</b>	<b>33%</b>
Other Operating Income	60.14	53.50	12%
Standalone Revenue from Operations	4367.43	3633.15	20%
Revenue from Operations - Subsidiaries	281.28	140.03	101%
Consolidated Revenue from Operations	4648.71	3773.18	23%
Other Income	67.00	57.68	16%
<b>Consolidated Net Total Income</b>	<b>4715.71</b>	<b>3830.86</b>	<b>23%</b>

#### About Ipca Laboratories:

Ipca is a pharmaceutical company with a strong thrust on exports which now account for 48% of Company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients.



Premchand Godha  
 Chairman & Managing Director



Encl: Audited Standalone & Consolidated Financial Results

#### Contact Information:

Harish P. Kamath, Corporate Counsel & Company Secretary at [harish.kamath@ipca.com](mailto:harish.kamath@ipca.com) or on +91-22- 6210 6050

Ipca Laboratories Ltd.  
[www.ipca.com](http://www.ipca.com)